Outset Medical insider tax sale: 388 shares sold, 46,495 remain

Rhea-AI Filing Summary

Outset Medical, Inc. reported an insider transaction by its General Counsel, John L. Brottem. On 11/17/2025, he sold 388 shares of common stock at $4.6 per share. The sale was required to cover tax withholding obligations tied to the vesting of 748 shares of common stock underlying restricted stock units granted on January 6, 2023 and January 12, 2024, and is described as a non-discretionary "sell to cover" transaction. After this trade, he directly holds 46,495 shares of Outset Medical common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brottem John L.

(Last) (First) (Middle)

3052 ORCHARD DRIVE

(Street)

SAN JOSE CA 95134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Outset Medical, Inc. [ OM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		S		388(1)	D	$4.6	46,495	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of an aggregate of 748 shares of Common Stock underlying RSUs granted to the reporting person on January 6, 2023, and January 12, 2024. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

	John L Brottem	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Outset Medical (OM) report in this Form 4?

The Form 4 reports that General Counsel John L. Brottem sold 388 shares of Outset Medical common stock on 11/17/2025 at a price of $4.6 per share.

Why did Outset Medical executive John L. Brottem sell 388 OM shares?

The sale of 388 shares was required to cover tax withholding obligations arising from the vesting of 748 RSU-based shares, executed as a non-discretionary "sell to cover" transaction.

How many Outset Medical (OM) shares does John L. Brottem own after the Form 4 trade?

Following the reported transaction, John L. Brottem beneficially owns 46,495 shares of Outset Medical common stock in direct ownership.

What equity awards were involved in this Outset Medical Form 4 transaction?

The tax-related sale is linked to the vesting of an aggregate of 748 shares of common stock underlying RSUs granted to John L. Brottem on January 6, 2023 and January 12, 2024.

Is the Form 4 sale by Outset Medical's General Counsel considered discretionary trading?

No. The filing states the sale "does not represent a discretionary trade" and was executed solely to satisfy tax withholding through a "sell to cover" transaction.

What is the role of the reporting person in this Outset Medical (OM) Form 4?

The reporting person, John L. Brottem, is an officer of Outset Medical, serving as its General Counsel, and filed the Form 4 as an individual reporting person.